Bluefin Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 115,989 shares of the company’s stock, valued at approximately $189,000.
Separately, Clear Street LLC acquired a new position in TriSalus Life Sciences in the fourth quarter valued at approximately $60,000.
TriSalus Life Sciences Price Performance
TLSIW stock opened at $1.01 on Wednesday. TriSalus Life Sciences, Inc. has a twelve month low of $0.10 and a twelve month high of $2.23. The business’s fifty day moving average is $1.28 and its 200-day moving average is $1.30.
TriSalus Life Sciences Profile
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Read More
- Five stocks we like better than TriSalus Life Sciences
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Trade Like a Member of Congress With These 2 ETFs
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- October’s Top 3 Stocks Revealed by MarketBeat’s MarketRank Tool
- P/E Ratio Calculation: How to Assess Stocks
- Chinese Stock Surge: Should You Invest After Stimulus Boost?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
